Sorrento's License Partner, Lee's Pharm, Announces Full - GlobeNewswire

Retrieved on: 2022-05-17 15:02:27

Tags for this article:

Clinical medicine

Cancer treatments

PD-1 and PD-L1 inhibitors

Small-cell carcinoma

Antibody-drug conjugate

China Oncology Focus Limited

Lee’s Pharm

Click the tags to see associated articles and topics

Sorrento's License Partner, Lee's Pharm, Announces Full - GlobeNewswire. View article details on HISWAI: https://www.globenewswire.com/news-release/2022/05/17/2445239/0/en/Sorrento-s-License-Partner-Lee-s-Pharm-Announces-Full-Enrollment-of-498-Patients-in-a-Phase-III-Trial-of-Socazolimab-Anti-PD-L1-Antibody-for-First-Line-Treatment-of-Extensive-Stage.html

Excerpt

Socazolimab (anti-PD-L1 monoclonal antibody) was discovered by Sorrento from its fully human antibody G-MABTM library and licensed by China ...

Article found on: www.globenewswire.com

View Original Article